



Opioid Attestation

Please provide the information below, attach supporting documentation, sign, date, and fax to Express Scripts at **1-877-251-5896** as soon as possible to expedite this request. Without this information, your request may be denied. Please call **800-753-2851** for assistance with submitting a prior authorization request. **This form is effective as of May 1, 2020.**

Patient name Patient date of birth Patient telephone Patient address Pharmacy name Pharmacy name Pharmacy NPI Pharmacy NPI Pharmacy telephone Pharmacy fax Prescriber NPI Prescriber telephone Prescriber fax Medication and strength Directions for use Qty/Days supply Medication and strength Directions for use Qty/Days supply Directions for use Qty/Days supply Medication and strength Directions for use Qty/Days supply Directions for use Qty/Days supply This form is required when patients begin chronic use of opioid, when daily opioid doses exceed 120 MME, or when both occur. Use of any opioid for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescriptions, which result in doses above 120 morphine milligram equivalents (MME) per day requires a mandatory consultation with a pain management specialist or be prescribed by section 3 a.i., 1-5. Chronic opioid use and doses above 120 MME may be unbrorized in 12 month intervals when the prescriber signs this attestation. If a prescriber wants an attestation to be authorized for less than 12 months, the prescriber wants and the section of the patients receiving policids for the treatment of pain relating to active cancer treatment, hospice, palliative or end-of-life care, the consultation is not required for authorization, but it is still encouraged. Please review the Prescriptions Montioning Program (PME) to verify all policids your patients teceriving use the SUPPORT ACL HCA MME Conversion Factor document (https://www.hca.wa.gov/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid 2. Line of the prescription o	Date of request	CHPW Member ID	ProviderOne ID		Diagnosis			
Medication and strength Directions for use Otty/Days supply This form is required when patients begin chronic use of opioid, when daily opioid doses exceed 120 MME, or when both occur. Use of any opioid for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescriptions, which result in doses above 120 morphile milligram equivalents (IMME) per day requires a mandatory consultation with a pain management specialist or be prescribed by a pain management specialist as defined by section 3 a.N.1-5. Chronic opioid use and doses above 120 MME may be authorized in 12 months, the prescriber must include a specific end date below. For patients receiving opioids for the treatment of pain relating to active cancer treatment, hospice, palliative or end-of-life care, the consultation is not required for authorization, but it is still encouraged. Please review the Prescription Monitoring Program (PMP) to verify all opioids your patient is currently receiving. Use the SUPPORT Act HCA MME Conversion Factor document (Ititus://www.hca.wa.acv/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid a. Acute pan-cancer pain is Specify MME	Patient name		Patient date of birth		Patient telephone		Patient address	
Medication and strength Directions for use Qty/Days supply Medication and strength Directions for use Qty/Days supply Medication and strength Directions for use Qty/Days supply This form is required when patients begin chronic use of opioid, when daily opioid doses exceed 120 MME, or when both occur. Use of any opioid for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescriptions, which result in doses above 120 morphine milligrame quivalents (MME) per day requires a mandatory consultation with a panamagement specialist or be prescribed by a pain management specialist as defined by section 3.a.iv.1-5. Chronic opioid use and doses above 120 MME may be authorized in 12 months, the prescriber wants an attestation to be authorized for less than 12 months, the prescriber must include a specific end date below. For patients receiving opioids for the treatment of pain relating to active cancer treatment, hospice, pallative or end-of-life care, the consultation is not required for authorization, but it is still encouraged. Please review the Prescription Monitoring Program (PMP) to verify all opioids your patient is currently receiving. Use the SUPPORT Act HCA MME Conversion Factor document (https://www.hca.wa.gov/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid 2. Intended use and dose of opioid 3. Listen of the prescription Monitoring Program (PMP) to verify all opioids your patient is currently receiving. Use the SUPPORT Act HCA MME Conversion Factor document (https://www.hca.wa.gov/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid 3. Listen of the prescription Monitoring Program (PMP) to verify all opioids your patients is currently received. Supply medical records supporting the medical need) be a 12 to but \$200 per day (Complete section 3 and 4); or 3. Li	Pharmacy name		Pharmacy NPI		Pharmacy telephone		Pharmacy fax	
Medication and strength Directions for use Oty/Days supply This form is required when patients begin chronic use of opioid, when daily opioid doses exceed 120 MME, or when both occur. Use of any opioid for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescription, which result in doses above 120 morphine milligram equivalents (MME) per day requires a mandatory consultation with a pain management specialist as defined by section 3.a.iv.15. Chronic lopid use and doses above 120 MME may be authorized in 12 month intervals when the prescriber signs this attestation. If a prescriber wants an attestation to be authorized for less than 12 months, the prescriber must include a specific end date below. For patients receiving opioids for the treatment of pain relating to active cancer treatment, hospice, palliative or end-of-life care, the consultation is not required for authorization, but it is still encouraged. Please review the Prescription Monitoring Program (PMP) to verify all opioids your patient is currently receiving. Use the SUPPORT Act HCA MME Conversion Factor document (https://www.hca.wa.gov/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid a. Acute pron-cancer pain. Specify MME:	Prescriber		Prescriber NPI		Prescriber telephone		Prescriber fax	
Medication and strength Directions for use Otty/Days supply This form is required when patients begin chronic use of opioid, when daily opioid doses exceed 120 MME, or when both occur. Use of any opioid for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescriptions, which result in doses above 120 morphine milligram equivalents (MME) per day requires a mandatory consultation with a pain management specialist or be prescribed by a pain management specialist as defined by section 3 a.i.v.1-5. Chronic opioid use and doses above 120 MME may be authorized in 12 month intervals when the prescriber signs this attestation. If a prescriber wants an attestation to be authorized for less than 12 months, the prescriber must include a specific end date below. For patients receiving opioids for the treatment of pain relating to active cancer treatment, hospice, palliative or end-of-life care, the consultation is not required for authorization, but it is still encouraged. Please review the Prescription Monitoring Program (PMP) to verify all opioids your patient is currently receiving. Use the SUPPORT Act HCA MME Conversion Factor document (https://www.hca.wa.exv/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid a. Acute pon-cancer pain. Specify MME:	Medication and strength			Directions for use		Qty/Days supply		
This form is required when patients begin chronic use of opioid, when daily opioid doses exceed 120 MME, or when both occur. Use of any opioid for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescriptions, which result in doses above 120 morphine milligram equivalents (MME) per day requires a mandatory consultation with a pain management specialist as defined by section 3 a.iv. 1-5. Chronic opioid use and doses above 120 MME may be authorized in 12 month intervals when the prescriber signs this attestation. If a prescriber wants an attestation to be authorized for less than 12 months, the prescriber must include a specific end date below. For patients receiving opioids for the treatment of pain relating to active cancer treatment, hospice, palliative or end-of-life care, the consultation is not required for authorization, but it is still encouraged. Please review the Prescription Monitoring Program (PMP) to verify all opioids your patient is currently receiving. Use the SUPPORT ACL HCA MME Conversion Factor document (https://www.hca.wa.gov/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid a. Acute nan-cancer pain. Specify MME: 1. Intended use and dose of opioid a. Acute nan-cancer pain. Specify MME: 3. Loo MME per day (Complete section 3 and 4); or 3. Loo MME per day (Complete section 2 thru 4); or 3. Loo MME per day (Complete section 2 thru 4); or 3. Loo MME per day (Complete section 2 thru 4); or 3. Loo MME per day (Complete section 2 thru 4); or 4. Loo MME: 4. Loo MME per day (Complete section 2 thru 4); or 4. Loo MME: 5. Loo MME per day (Pharmacy may re-submit claim with EA Code: 85000000540); or 6. Loo MME per day (Complete section 3 and 4); or 7. Loo MME per day (Pharmacy may re-submit claim with EA Code: 85000000540); or 8. Loo MME per day (Complete section 3 and 4; supply medical records supporting the medical need) 9. Loo	Medication and strength			Directions for use		Qty/Days supply		
for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescriptions, which result in doses above 120 morphine milligram equivalents (MME) per day requires a mandatory consultation with a pain management specialist or be prescribed by a pain management specialist as defined by section 3.a.iv.1-5. Chronic opioid use and doses above 120 MME may be authorized in 12 month intervals when the prescriber may be section 3.a.iv.1-5. Chronic opioid so the treatment of pain relating to active cancer treatment, hospice, palliative or end-of-life care, the consultation is not required for authorization, but it is still encouraged. Please review the Prescription Monitoring Program (PMP) to verify all opioids your patient is currently receiving. Use the SUPPORT Act HCA MME Conversion Factor document (https://www.hca.wa.gov/billers-providers-partners/programs-and-services/opioids) to calculate the total prescribed MME. 1. Intended use and dose of opioid 2. Intended use and dose of opioid 3. Actue apon-cancer pain. Specify MME:	Medication and strength			Directions for use	tions for use Qty/Da		ys supply	
Intended use and dose of opioid a. Acute non-cancer pain. Specify MME:	for more than 42 days within a 90 day period is considered chronic use. Use of opioids, either as a single prescription or multiple prescriptions, which result in doses above 120 morphine milligram equivalents (MME) per day requires a mandatory consultation with a pain management specialist or be prescribed by a pain management specialist as defined by section 3.a.iv.1-5. Chronic opioid use and doses above 120 MME may be authorized in 12 month intervals when the prescriber signs this attestation. If a prescriber wants an attestation to be authorized for less than 12 months, the prescriber must include a specific end date below. For patients receiving opioids for the treatment of pain relating to active cancer treatment,							
MME. 1. Intended use and dose of opioid a.								
a. Acute non-cancer pain. Specify MME: i. > 120 but ≤ 200 per day (Complete section 3 and 4); or ii. > 200 MME per day (Complete section 3 and 4; supply medical records supporting the medical need) b. Chronic non-cancer pain (> 42 days of opioid therapy is needed in a 90 day period). Specify MME: > 120 but ≤ 200 per day (Complete sections 2 and 4) > 120 but ≤ 200 per day (Complete section 2 thru 4); or > 120 but ≤ 200 per day (Complete section 2 thru 4); or > 120 but ≤ 200 per day (Complete section 2 thru 4; supply medical records supporting the medical need) > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or > 120 but ≤ 200 per day (Complete section 3 and 4); or								
i. > 120 but ≤ 200 per day (Complete section 3 and 4); or > 200 MME per day (Complete section 3 and 4; supply medical records supporting the medical need) b. Chronic non-cancer pain (> 42 days of opioid therapy is needed in a 90 day period). Specify MME:								
ii. > 200 MME per day (Complete section 3 and 4; supply medical records supporting the medical need) Chronic non-cancer pain < 42 days of opioid therapy is needed in a 90 day period). Specify MME:								
b.								
i. < 120 MME per day (Complete sections 2 and 4) ii. > 120 but < 200 per day (Complete section 2 thru 4); or iii. > 200 MME per day (Complete section 2 thru 4; supply medical records supporting the medical need) c. Active cancer pain, hospice, palliative, or end-of-life care. Specify MME:	ii. \longrightarrow > 200 ivilvie per day (Complete section 3 and 4; supply medical records supporting the medical need)							
ii.								
c.								
c. Active cancer pain, hospice, palliative, or end-of-life care. Specify MME: i.								
i.								
2. Chronic Opioid Attestation a. Criteria for chronic use of opioids for the treatment of non-cancer pain: i. My patient has an on-going clinical need for chronic opioid use at the prescribed dose (more than 42 days per 90 day calendar period) that is documented in the medical record; AND ii. My patient is using appropriate non-opioid medications, and/or non-pharmacologic therapies; OR iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of								
 2. Chronic Opioid Attestation a. Criteria for chronic use of opioids for the treatment of non-cancer pain: i. My patient has an on-going clinical need for chronic opioid use at the prescribed dose (more than 42 days per 90 day calendar period) that is documented in the medical record; AND ii. My patient is using appropriate non-opioid medications, and/or non-pharmacologic therapies; OR iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
 a. Criteria for chronic use of opioids for the treatment of non-cancer pain: i. My patient has an on-going clinical need for chronic opioid use at the prescribed dose (more than 42 days per 90 day calendar period) that is documented in the medical record; AND ii. My patient is using appropriate non-opioid medications, and/or non-pharmacologic therapies; OR iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
 a. Criteria for chronic use of opioids for the treatment of non-cancer pain: i. My patient has an on-going clinical need for chronic opioid use at the prescribed dose (more than 42 days per 90 day calendar period) that is documented in the medical record; AND ii. My patient is using appropriate non-opioid medications, and/or non-pharmacologic therapies; OR iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 	2 Chronic Onicid Attortation							
 i. My patient has an on-going clinical need for chronic opioid use at the prescribed dose (more than 42 days per 90 day calendar period) that is documented in the medical record; AND ii. My patient is using appropriate non-opioid medications, and/or non-pharmacologic therapies; OR iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND viii. I conduct periodic urine drug screens of my patient; AND viiii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 		•	nioids for th	ne treatment of non-can	cor nain:			
 90 day calendar period) that is documented in the medical record; AND ii. My patient is using appropriate non-opioid medications, and/or non-pharmacologic therapies; OR iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
 ii. My patient is using appropriate non-opioid medications, and/or non-pharmacologic therapies; OR iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND viii. I conduct periodic urine drug screens of my patient; AND viiii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
 iii. My patient has tried and failed non-opioid medications and non-pharmacologic therapies for the treatment of this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND viii. I conduct periodic urine drug screens of my patient; AND viiii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
 this pain condition; AND iv. For long-acting opioids, my patient has tried a short-acting opioid for at least 42 days or there is clinical justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
justification why short-acting opioids were inappropriate or ineffective; AND v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of						_		
 v. I have recorded your patient's baseline objective pain and function scores and conduct periodic assessments in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND viii. I conduct periodic urine drug screens of my patient; AND viiii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 						lays or there is clinical		
in order to demonstrate clinically meaningful improvements in pain and function; AND vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of			_				nduct periodic assessments	
 vi. I have screened my patient for mental health disorders, substance use disorder, naloxone use; AND vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
 vii. I conduct periodic urine drug screens of my patient; AND viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
 viii. I check the PDMP to determine if my patient is receiving other opioid therapy and concurrent therapy with benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of 								
benzodiazepines and other sedatives; AND ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of			_			nerapy and	concurrent therapy with	
ix. I discussed with my patient the realistic goals of pain management therapy, including discontinuation of					- '	.,	, ,	
					management ther	apy, includ	ding discontinuation of	
		opioid therapy as	an option d	luring treatment; AND				
 I have confirmed that my patient understands and accepts these conditions and my patient has signed a pain contract or informed consent document. 					cepts these condit	ions and n	ny patient has signed a pain	

·	treatment is medically necessary, does not exce my patient's medical record:	ed the medical needs of the member, and is Yes $\ \square$ No			
c. I attest that all more are not a		entation in my patient's medical record for why one or No			
i.	for opioid doses MME > 120 per day, including of the patient has active cancer pain, palliative care, ge that exceeds 120 MME per day; OR My patient has a medically necessary need requir lay, for no more than 42 days; AND (check the both of the lay, for no more than 42 days; AND (check the both of lay, for no more than 42 days; AND (check the both of lay, for no more than 42 days; AND (check the both of lay, for no more than 42 days; AND (check the both of lay) and understand prescriber, and I have coordinated care with 2. I am the prescriber of the chronic opiois 3. I am prescribing opioids for my patient for one lay and lay patient is following a tapering schedule with a material patient has a medically necessary need to exceed a my patient has a medically necessary need to exceed the lay and lay a pain management specialist as decently and lay a pain management within the previous been dedicated to substance use disorders; and lam a pain management physician work center or a multidisciplinary academic reservation. I have a minimum of three years of clin and at least thirty percent of their current pore of lay for this patient through one medical record: a. An office visit with patient, prescriber; OR c. An audio-visual evaluation conduct the patient is present with either designated by the physician or the patient is medically necessary, does not exceed my patient's medical record: of the above criteria are met, or there is document of the above criteria are met, or there is document.	end of life care or is in hospice requiring an opioid ring a temporary opioid dosage that exceeds 120 MME ox below that applies): edically necessary need, I have reviewed the Prescription I my patient is on chronic opioid therapy from another the other opioid prescriber; OR d therapy; OR one of the following reasons: starting dose > 120 MME per day; OR eded 120 MME per day documented in the medical efined in WAC 246-919-945; OR m of twelve category I continuing education hours on ous four years. At least two of these hours must have i OR king in a multidisciplinary chronic pain treatment arch facility; OR ical experience in a chronic pain management setting, viractice is the direct provision of pain management care; ant specialist regarding use of high dose opioids (> 120 of the methods below and it is documented in the iber and pain management specialist; OR on consultation between the pain management specialist ceted by the pain management specialist remotely where the physician or a licensed health care practitioner e pain management specialist. ed the medical needs of the member, and is Yes No entation in my patient's medical record for why one or			
will expire in 12 months	oses that exceed 120 MME per day, this attestat unless you specify that you would like an earlier if you would like an earlier end date:	ion will expire in 42 days; for all others this attestation end date.			
By signing below, I certify that the information on this form is true and understand that any misrepresentation or any concealment of any information requested may subject me to an audit. Supporting documentation is required for requests exceeding 200 MME per day.					
Prescriber signature	Prescriber specialty	Date			